These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 10087580)

  • 21. A remarkable improvement of clinical manifestations in a breast cancer patient with widespread bone metastases after administration of pamidronate.
    Kage K; Nagahama T; Sekine I; Maruyama M; Ogata E
    Intern Med; 1997 Dec; 36(12):926-30. PubMed ID: 9475253
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Bisphosphonates in the prevention and treatment of bone metastases.
    Ramaswamy B; Shapiro CL
    Oncology (Williston Park); 2003 Sep; 17(9):1261-70; discussion 1270-2, 1277-8, 1280. PubMed ID: 14569853
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Nephrotic-range proteinuria following pamidronate therapy in a patient with metastatic breast cancer: mitochondrial toxicity as a pathogenetic concept?
    Sauter M; Jülg B; Porubsky S; Cohen C; Fischereder M; Sitter T; Schlondorff D; Gröne HJ
    Am J Kidney Dis; 2006 Jun; 47(6):1075-80. PubMed ID: 16731304
    [No Abstract]   [Full Text] [Related]  

  • 24. Clinical trials in metastatic breast cancer to bone: past--present--future.
    Body JJ
    Can J Oncol; 1995 Dec; 5 Suppl 1():16-27. PubMed ID: 8853520
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Adjuvant bisphosphonate therapy for breast cancer patients: Standard of care or future direction?
    Freedman OC; Amir E; Clemons MJ
    Crit Rev Oncol Hematol; 2009 Oct; 72(1):56-64. PubMed ID: 19307138
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Bisphosphonates in the adjuvant treatment of cancer: experimental evidence and first clinical results. International Bone and Cancer Study Group (IBCG).
    Diel IJ; Mundy GR
    Br J Cancer; 2000 Apr; 82(8):1381-6. PubMed ID: 10780514
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Metastatic bone disease: role of bisphosphonates.
    McKenna MJ; Freaney R; Crown J
    Ir Med J; 1995; 88(6):189. PubMed ID: 8575911
    [No Abstract]   [Full Text] [Related]  

  • 28. Bisphosphonates may be useful in treatment of bone metastases.
    Jones J
    J Natl Cancer Inst; 2001 Jul; 93(14):1052-3. PubMed ID: 11459865
    [No Abstract]   [Full Text] [Related]  

  • 29. Combined analysis of two multicenter, randomized, placebo-controlled studies of pamidronate disodium for the palliation of bone pain in men with metastatic prostate cancer.
    Small EJ; Smith MR; Seaman JJ; Petrone S; Kowalski MO
    J Clin Oncol; 2003 Dec; 21(23):4277-84. PubMed ID: 14581438
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Current use of bisphosphonates in clinical oncology].
    Vrbanec D; Plestina S; Belev B; Unusić J; Pavlinić-Diminić V
    Lijec Vjesn; 1999; 121(9-10):296-301. PubMed ID: 19658372
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A phase I study of AMGN-0007, a recombinant osteoprotegerin construct, in patients with multiple myeloma or breast carcinoma related bone metastases.
    Body JJ; Greipp P; Coleman RE; Facon T; Geurs F; Fermand JP; Harousseau JL; Lipton A; Mariette X; Williams CD; Nakanishi A; Holloway D; Martin SW; Dunstan CR; Bekker PJ
    Cancer; 2003 Feb; 97(3 Suppl):887-92. PubMed ID: 12548591
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Time and labor costs associated with administration of intravenous bisphosphonates for breast or prostate cancer patients with metastatic bone disease: a time and motion study.
    Xie F; Hopkins RB; Burke N; Habib M; Angelis CD; Pasetka M; Giotis A; Goeree R
    Hosp Pract (1995); 2014 Apr; 42(2):38-45. PubMed ID: 24769783
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Phase II trial evaluating the palliative benefit of second-line zoledronic acid in breast cancer patients with either a skeletal-related event or progressive bone metastases despite first-line bisphosphonate therapy.
    Clemons MJ; Dranitsaris G; Ooi WS; Yogendran G; Sukovic T; Wong BY; Verma S; Pritchard KI; Trudeau M; Cole DE
    J Clin Oncol; 2006 Oct; 24(30):4895-900. PubMed ID: 17001071
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Bisphosphonates for cancer patients: why, how, and when?
    Body JJ; Mancini I
    Support Care Cancer; 2002 Jul; 10(5):399-407. PubMed ID: 12136223
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Off-trial evaluation of bisphosphonates in patients with metastatic breast cancer.
    Liauw W; Segelov E; Lih A; Dunleavy R; Links M; Ward R
    BMC Cancer; 2005 Jul; 5():89. PubMed ID: 16048654
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Zoledronic acid: multiplicity of use across the cancer continuum.
    Lipton A
    Expert Rev Anticancer Ther; 2011 Jul; 11(7):999-1012. PubMed ID: 21806323
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Biphosphonates in breast cancer--based on a Cochrane meta-analysis].
    Junker N; Nielsen DL; Kamby C
    Ugeskr Laeger; 2007 Sep; 169(37):3108-11. PubMed ID: 17877961
    [No Abstract]   [Full Text] [Related]  

  • 38. Bisphosphonates in the treatment of malignant bone disease.
    Berenson JR; Lipton A
    Annu Rev Med; 1999; 50():237-48. PubMed ID: 10073275
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Zoledronic acid: past, present and future roles in cancer treatment.
    Saad F
    Future Oncol; 2005 Apr; 1(2):149-59. PubMed ID: 16555985
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Bisphosphonates for breast cancer: questions answered, questions remaining.
    Layman R; Olson K; Van Poznak C
    Hematol Oncol Clin North Am; 2007 Apr; 21(2):341-67. PubMed ID: 17512453
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.